ValuEngine upgraded shares of Cytori Therapeutics Inc (NASDAQ:CYTX) from a strong sell rating to a sell rating in a research note released on Thursday.
Several other equities analysts have also weighed in on the company. Zacks Investment Research lowered Cytori Therapeutics from a hold rating to a sell rating in a report on Monday, March 20th. Maxim Group set a $10.00 price objective on Cytori Therapeutics and gave the company a buy rating in a report on Wednesday, May 31st. Finally, B. Riley reissued a buy rating and set a $6.75 price objective on shares of Cytori Therapeutics in a report on Monday, March 27th.
Cytori Therapeutics (NASDAQ CYTX) traded down 2.61% during mid-day trading on Thursday, reaching $1.12. The company had a trading volume of 426,572 shares. The company’s 50-day moving average is $1.03 and its 200-day moving average is $1.38. Cytori Therapeutics has a one year low of $0.90 and a one year high of $2.29. The stock’s market capitalization is $36.38 million.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. Cytori Therapeutics had a negative return on equity of 329.82% and a negative net margin of 468.86%. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $2.32 million. During the same period in the prior year, the company earned ($0.03) earnings per share. Cytori Therapeutics’s revenue was down 53.8% compared to the same quarter last year. Equities research analysts anticipate that Cytori Therapeutics will post ($0.90) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/07/14/cytori-therapeutics-inc-cytx-upgraded-to-sell-at-valuengine.html.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. boosted its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 10.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 439,679 shares of the biotechnology company’s stock after buying an additional 40,839 shares during the period. Perkins Capital Management Inc. owned approximately 1.87% of Cytori Therapeutics worth $703,000 at the end of the most recent reporting period. 8.70% of the stock is currently owned by institutional investors and hedge funds.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.